Jason S. Lewis is a British radiochemist whose work relates to oncologic therapy and diagnosis. His research focus is a molecular imaging-based program focused on radiopharmaceutical development as well as the study of multimodality (PET, CT & MRI) small- and biomolecule-based agents and their clinical translation. He has worked on the development of small molecules as well as radiolabeled peptides and antibodies probing the overexpression of receptors and antigens on tumors.
Education
Jason S. Lewis was born and raised in Horndean, Hampshire, England. Lewis received his Bachelor of Science in chemistry, B.Sc. from the University of Essex in 1992. He received his Master of Science in chemistry from the University of Essex in 1993. In 1996, he received his Doctor of Philosophy in Biochemistry at the University of Kent.
Career Lewis taught Radiology at the Washington University School of Medicine, Mallinckrodt Institute of Radiology from 2000 to 2008. He is the Emily Tow Jackson Chair in Oncology, the Vice Chairman for Research (Radiology) and Chief Attending of the Radiochemistry and Imaging Sciences Service at Memorial Sloan Kettering Cancer Center. He also heads a laboratory in the Sloan Kettering Institute's Molecular Pharmacology Program and is a professor at the Gerstner Sloan Kettering Graduate School of Biomedical Sciences. Lewis holds joint appointments in the Departments of Radiology and the Department of Pharmacology at Weill Cornell Medical School, NY.
Research focus Lewis is a proponent of development imaging tools for use in personalized medicine. Lewis designs and develops radiochemical probes for use in nuclear medicine as well as multi-modality molecular imaging. The use of these probes span from oncological metabolic detection to understanding the biological processes of cancer and pharmacological modification. These probes can be used for biomarkers in clinical trials as well as used as an agent for oncological diagnostics. He has developed multiple new small molecules that target tumor metabolism, as well as radiolabeled peptides and antibodies for use in probing overexpression of receptors and antigens on tumors for research, clinical trials and in the clinic.
Recognition 2014 Distinguished Investigator Award from the Academy of Radiology Research Fellow, World Molecular Imaging Society (FWMIS) 2017 Michael J. Welch Award, Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2019 Paul C. Aebersold Award, Educational and Research Fund for Nuclear Medicine and Molecular Imaging (ERF) & Society of Nuclear Medicine and Molecular Imaging 2019 Fellow, Society of Nuclear Medicine and Molecular Imaging (FSNMMI)
Editorial board memberships Molecular Imaging and Biology (Editor-in-Chief) Journal of Nuclear Medicine (Associate Editor) ACS Bioconjugate Chemistry (Editorial Advisory Board) Nuclear Medicine and Biology (Associate Editor-in-Chief)
Selected Publications Pratt EC, Mandleywala K, Bauer D, Bolaender A, Chao G, Castanares MA, Collins EC, Lewis JS. ImmunoPET for mesothelin positive tissues using bio-orthogonal in-vivo click chemistry. Nucl Med Biol. 2025 Jul 15;148-149:109051. doi: 10.1016/j.nucmedbio.2025.109051. [Epub ahead of print] PubMed PMID: 40694891; PubMed Central PMCID: PMC12328198. Mack KN, Bauer D, Carter LM, Carrasco SE, Atmane MI, Viray TD, Brooks CL, Hollingsworth MA, Radhakrishnan P, Lewis JS. Pretargeted alpha therapy in MUC16-positive high-grade serous ovarian cancer. Nucl Med Biol. 2025 Jan-Feb;140-141:108976. doi: 10.1016/j.nucmedbio.2024.108976. Epub 2024 Nov 22. PubMed PMID: 39615062; PubMed Central PMCID: PMC12404150. Mahajan S, Grkovski M, Staton KD, Ravassa S, Domfe K, Strauss HW, Humm JL, Zanzonico PB, Beattie BJ, Cho I, Burnazi EM, Fox JJ, Schöder H, Osborne JR, Youn T, Jhaveri K, Chiosis G, Dunphy MP. Epichaperome-targeted myocardial imaging by (124)I-PU-H71 PET. Clin Transl Imaging. 2024 Dec;12(6):619-627. doi: 10.1007/s40336-024-00658-9. Epub 2024 Sep 20. PubMed PMID: 39935517; PubMed Central PMCID: PMC11810128. Bauer D, De Gregorio R, Pratt EC, Bell A, Michel A, Lewis JS. Examination of the PET in vivo generator (134)Ce as a theranostic match for (225)Ac. Eur J Nucl Med Mol Imaging. 2024 Nov;51(13):4015-4025. doi: 10.1007/s00259-024-06811-w. Epub 2024 Jun 28. PubMed PMID: 38940841; PubMed Central PMCID: PMC12121724. Sarrett SM, Rodriguez C, Delaney S, Hosny MM, Sebastiano J, Santos-Coquillat A, Keinänen OM, Carter LM, Lastwika KJ, Lampe PD, Zeglis BM. Evaluating CD133 as a Radiotheranostic Target in Small-Cell Lung Cancer. Mol Pharm. 2024 Mar 4;21(3):1402-1413. doi: 10.1021/acs.molpharmaceut.3c01063. Epub 2024 Feb 8. PubMed PMID: 38331430; PubMed Central PMCID: PMC10915790. Arroyo A, Lyashchenko SK, Lewis JS. Methods for the Production of Radiolabeled Bioagents for ImmunoPET. Methods Mol Biol. 2024;2729:117-142. doi: 10.1007/978-1-0716-3499-8_8. Review. PubMed PMID: 38006494; PubMed Central PMCID: PMC11330323. Chiosis G, Digwal CS, Trepel JB, Neckers L. Structural and functional complexity of HSP90 in cellular homeostasis and disease. Nat Rev Mol Cell Biol. 2023 Nov;24(11):797-815. doi: 10.1038/s41580-023-00640-9. Epub 2023 Jul 31. Review. PubMed PMID: 37524848; PubMed Central PMCID: PMC10592246. Zeglis BM, Lewis JS. Click Here for Better Chemistry. N Engl J Med. 2022 Dec 15;387(24):2291-2293. doi: 10.1056/NEJMcibr2213596. Epub 2022 Nov 30. PubMed PMID: 36449446; PubMed Central PMCID: PMC10501737. Ginsberg SD, Sharma S, Norton L, Chiosis G. Targeting stressor-induced dysfunctions in protein-protein interaction networks via epichaperomes. Trends Pharmacol Sci. 2023 Jan;44(1):20-33. doi: 10.1016/j.tips.2022.10.006. Epub 2022 Nov 20. Review. PubMed PMID: 36414432; PubMed Central PMCID: PMC9789192. Maitz CA, Delaney S, Cook BE, Genady AR, Hoerres R, Kuchuk M, Makris G, Valliant JF, Sadeghi S, Lewis JS, Hennkens HM, Bryan JN, Zeglis BM. Pretargeted PET of Osteodestructive Lesions in Dogs. Mol Pharm. 2022 Sep 5;19(9):3153-3162. doi: 10.1021/acs.molpharmaceut.2c00220. Epub 2022 May 30. PubMed PMID: 35635337; PubMed Central PMCID: PMC10316029.
References
